PL Capital expect Sai to deliver ~21% revenue compound annual growth rate over FY26–29E, with broad-based growth across CRO and CDMO. The CRO business should provide a steady base, supported by continued demand from large pharma's, while contract development manufacturing organisation growth should be driven by the progression of its late-stage pipeline and increasing contribution from commercial molecules. With 14 late-stage molecules and a broader portfolio progressing through development, we see meaningful scope for commercialization-led growth over the medium term.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
PL Capital Report
PL Capital has initiated coverage on Sai Life Sciences Ltd. with ‘Buy' rating and has set a target price of Rs 1,620/share.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Sai has built an integrated CRDMO platform spanning discovery, development and manufacturing, with a proven track record of supporting complex pharma and biotech programs.
It is well placed to benefit from the shift toward outsourcing in small molecules, given its integrated capabilities across discovery, development and manufacturing and strong process chemistry expertise.
The brokerage sees large-pharma engagements as the key near-term growth driver, with the discovery platform providing a steady funnel of projects that can move into development and subsequently commercial manufacturing.
The deep late-stage and commercial pipelines should further support growth. Planned capex of Rs 1,100-1,300 crore for FY27E and rising wallet share from existing customers provide additional upside.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
